DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 208552
NDA 208552 describes RHOFADE, which is a drug marketed by Allergan Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the RHOFADE profile page.
The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
Summary for 208552
| Tradename: | RHOFADE |
| Applicant: | Allergan Inc |
| Ingredient: | oxymetazoline hydrochloride |
| Patents: | 4 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 208552
| Ingredient-type | Imidazolines |
| Physiological Effect | Vasoconstriction Increased Sympathetic Activity |
Medical Subject Heading (MeSH) Categories for 208552
Suppliers and Packaging for NDA: 208552
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552 | NDA | Allergan | 0023-5300 | N | 0023-5300-30 |
| RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552 | NDA | Allergan | 0023-5300 | N | 0023-5300-35 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CREAM;TOPICAL | Strength | 1% | ||||
| Approval Date: | Jan 18, 2017 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jan 18, 2020 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Patent: | ➤ Sign Up | Patent Expiration: | May 2, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM | ||||||||
| Patent: | ➤ Sign Up | Patent Expiration: | Aug 2, 2024 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM | ||||||||
Complete Access Available with Subscription
